Workplace Drug Testing in Europe: How It Compared to the US in 2001 | Research

The takeaway

A review found that workplace drug testing in Europe was far less developed than in the US, with minimal legislation, inconsistent quality control, and cannabis as the most frequently detected substance.

Read this if you want to understand how workplace drug testing for cannabis developed differently in Europe versus the United States.

Cannabis was the most frequently detected drug in European workplace tests

What the researchers found

Workplace drug testing in Europe lacked the standardized infrastructure found in the United States. There was no specific legislation and no generally accepted guidelines across Europe. Many companies established drug policies with little or no actual testing provisions. When testing was performed, it was often done on-site by occupational physicians with minimal quality control, no systematic confirmation of positive results, no chain of custody, and no adulteration testing.

Testing was growing in the UK and Scandinavian countries but remained uncommon elsewhere in Europe. The most frequently tested substances were amphetamines, cannabinoids, cocaine, opiates, and alcohol. Cannabis was the drug most frequently detected. Positive test rates appeared to decrease in the years following the introduction of workplace drug testing programs.

Why it matters

This review documented a significant gap between European and American approaches to workplace drug testing at a time when cannabis policy was diverging internationally. The finding that cannabis was the most commonly detected drug in European workplace testing raised questions about whether these programs disproportionately captured cannabis users, given cannabis's longer detection window compared to other substances.

The numbers in context

No specific prevalence data or positive rates were reported in detail. The review noted that positive rates generally decreased after workplace drug testing programs were introduced.

How the study worked

This was a descriptive review of the state of workplace drug testing practices across Europe, including information about legislation, testing procedures, quality standards, and recent organizational developments such as the founding of the European Workplace Drug Testing Society (EWDTS).

What this study cannot tell us

This was a descriptive overview rather than a systematic review. Specific data on testing rates, positive rates, and outcomes across European countries were sparse. The review reflected the state of practice in 2001 and much has changed since then in both regulation and technology.

How to read the evidence

This is a descriptive review of workplace testing practices without systematic methodology, providing preliminary-level evidence.

When this study was published

Published in 2001. Workplace drug testing practices and cannabis laws have changed significantly across Europe since this review.

The bigger picture

The landscape described in this review has continued to evolve. As more jurisdictions legalize or decriminalize cannabis, the role of workplace drug testing for cannabis has become increasingly contested. Some employers have removed cannabis from their testing panels, while others maintain testing for safety-sensitive positions.

Questions still open

Does workplace drug testing for cannabis actually improve workplace safety outcomes? How should workplace testing policies adapt to jurisdictions where cannabis is legal? Does the long detection window for cannabis create an inherent bias in workplace testing programs?

Common questions

Is cannabis the most common drug found in workplace testing?

In 2001 European testing, yes. Cannabis was the most frequently detected substance, which may partly reflect its longer detection window in urine (weeks vs. days for most other drugs) rather than higher rates of impaired work performance.

Are European workplace drug testing standards better now?

The European Workplace Drug Testing Society (EWDTS) was founded around this time and has since worked to establish quality guidelines. However, workplace drug testing practices still vary significantly across European countries.

Read the original research

Workplace drug testing in Europe.

Forensic science international, 121(1-2), 2-6

View on PubMed ↗

Citation

Verstraete, A G; Pierce, A. (2001). Workplace drug testing in Europe.. Forensic science international, 121(1-2), 2-6.